140 related articles for article (PubMed ID: 37882554)
1. The inhibition of IRE1alpha/XBP1 axis prevents EBV-driven lymphomagenesis in NSG mice.
Arena A; Romeo MA; Po A; Benedetti R; Gilardini Montani MS; Gonnella R; Santarelli R; Gaeta A; De Smaele E; Cirone M
Microbiol Spectr; 2023 Dec; 11(6):e0263623. PubMed ID: 37882554
[TBL] [Abstract][Full Text] [Related]
2. Concomitant Inhibition of IRE1α/XBP1 Axis of UPR and PARP: A Promising Therapeutic Approach against c-Myc and Gammaherpesvirus-Driven B-Cell Lymphomas.
Benedetti R; Arena A; Romeo MA; Gilardini Montani MS; Gonnella R; Santarelli R; Trivedi P; Cirone M
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012375
[TBL] [Abstract][Full Text] [Related]
3. In vivo intratumoral Epstein-Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications.
Gonzalez-Farre B; Rovira J; Martinez D; Valera A; Garcia-Herrera A; Marcos MA; Sole C; Roue G; Colomer D; Gonzalvo E; Ribera-Cortada I; Araya M; Lloreta J; Colomo L; Campo E; Lopez-Guillermo A; Martinez A
Mod Pathol; 2014 Dec; 27(12):1599-611. PubMed ID: 24762547
[TBL] [Abstract][Full Text] [Related]
4. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
6. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors.
White RE; Rämer PC; Naresh KN; Meixlsperger S; Pinaud L; Rooney C; Savoldo B; Coutinho R; Bödör C; Gribben J; Ibrahim HA; Bower M; Nourse JP; Gandhi MK; Middeldorp J; Cader FZ; Murray P; Münz C; Allday MJ
J Clin Invest; 2012 Apr; 122(4):1487-502. PubMed ID: 22406538
[TBL] [Abstract][Full Text] [Related]
7. Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice.
Liu X; Guo GL; Kong B; Hilburn DB; Hubchak SC; Park S; LeCuyer B; Hsieh A; Wang L; Fang D; Green RM
Hepatology; 2018 Jul; 68(1):304-316. PubMed ID: 29377207
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
[TBL] [Abstract][Full Text] [Related]
9. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
[TBL] [Abstract][Full Text] [Related]
10. IRE1α-XBP1 pathway promotes melanoma progression by regulating IL-6/STAT3 signaling.
Chen C; Zhang X
J Transl Med; 2017 Feb; 15(1):42. PubMed ID: 28222747
[TBL] [Abstract][Full Text] [Related]
11. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV
Martínez LE; Daniels-Wells TR; Guo Y; Magpantay LI; Candelaria PV; Penichet ML; Martínez-Maza O; Epeldegui M
Mol Cancer Ther; 2021 Sep; 20(9):1592-1602. PubMed ID: 34158342
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
[TBL] [Abstract][Full Text] [Related]
14. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
[TBL] [Abstract][Full Text] [Related]
15. The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.
Robert A; Pujals A; Favre L; Debernardi J; Wiels J
Mol Oncol; 2020 Oct; 14(10):2520-2532. PubMed ID: 32623836
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia.
Sun H; Lin DC; Guo X; Kharabi Masouleh B; Gery S; Cao Q; Alkan S; Ikezoe T; Akiba C; Paquette R; Chien W; Müller-Tidow C; Jing Y; Agelopoulos K; Müschen M; Koeffler HP
Oncotarget; 2016 Apr; 7(14):18736-49. PubMed ID: 26934650
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus (EBV) and lymphomagenesis.
Cesarman E
Front Biosci; 2002 Feb; 7():e58-65. PubMed ID: 11815280
[TBL] [Abstract][Full Text] [Related]
18. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Imadome KI; Mizukami Y; Okumura T
Medicine (Baltimore); 2022 Mar; 101(12):e29055. PubMed ID: 35357349
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for PTLD diagnosis and therapies.
Martinez OM
Pediatr Nephrol; 2020 Jul; 35(7):1173-1181. PubMed ID: 31240394
[TBL] [Abstract][Full Text] [Related]
20. IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment.
Harnoss JM; Le Thomas A; Reichelt M; Guttman O; Wu TD; Marsters SA; Shemorry A; Lawrence DA; Kan D; Segal E; Merchant M; Totpal K; Crocker LM; Mesh K; Dohse M; Solon M; Modrusan Z; Rudolph J; Koeppen H; Walter P; Ashkenazi A
Cancer Res; 2020 Jun; 80(11):2368-2379. PubMed ID: 32265225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
